Markus Barten News Today

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the publication of findings from a retrospective, observational, single arm, European chart review study assessing the real-world use of extracorporeal photopheresis (ECP) and its impact on clinical outcomes in the modern era of heart transplantation.1 An online version of the data manuscript – the largest-known study of ECP in heart transplant patients – is currently published on the ...

Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of extracorporeal photopheresis (ECP) in heart transplant patients reinforce its use as a treatment for heart transplant rejection and prevention of rejection.

- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its

EQS-News: Biotest AG / Key word(s): StudyBiotest AG: First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation 24.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE   First patient treated with Cytotect® CP&n...

24.01.2023 - EQS-News: Biotest AG / Key word(s): Study Biotest AG: First patient treated with Cytotect CP Biotest in study after heart and lung transplantation 24.01.2023 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement.   ... Seite 1

EQS-News: Biotest AG / Key word(s): Study Biotest AG: First patient treated with Cytotect® CP Biotest in study after heart and l...